Louisiana State Employees Retirement System Makes New Investment in Halozyme Therapeutics, Inc. $HALO

Louisiana State Employees Retirement System purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 34,100 shares of the biopharmaceutical company’s stock, valued at approximately $2,204,000.

Several other large investors have also recently modified their holdings of HALO. DLD Asset Management LP grew its stake in shares of Halozyme Therapeutics by 20.0% in the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock worth $2,200,200,000 after purchasing an additional 5,000,000 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in Halozyme Therapeutics by 29.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after purchasing an additional 749,484 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Halozyme Therapeutics by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock worth $141,613,000 after purchasing an additional 25,731 shares during the last quarter. Norges Bank acquired a new position in Halozyme Therapeutics during the 4th quarter worth about $128,201,000. Finally, William Blair Investment Management LLC acquired a new position in Halozyme Therapeutics during the 4th quarter worth about $124,031,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 3.0%

Shares of NASDAQ:HALO opened at $77.18 on Tuesday. The business’s 50 day simple moving average is $68.64 and its two-hundred day simple moving average is $69.01. The firm has a market cap of $9.15 billion, a P/E ratio of 27.76, a PEG ratio of 0.31 and a beta of 0.88. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. Halozyme Therapeutics, Inc. has a 52-week low of $51.06 and a 52-week high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. During the same quarter in the previous year, the company posted $1.11 earnings per share. The company’s quarterly revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $69.07, for a total value of $690,700.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $53,030,564.60. This trade represents a 1.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $66.21, for a total transaction of $107,591.25. Following the sale, the director owned 43,669 shares of the company’s stock, valued at $2,891,324.49. This trade represents a 3.59% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 93,250 shares of company stock valued at $6,299,746. 2.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on HALO shares. Morgan Stanley decreased their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. UBS Group reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, June 16th. Finally, Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $81.60.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.